Both methods have their strengths
392 Ipatasertib prolonged PSA progression-free interval and overall survival compared to the placebo group in a phase 2 trial
Like many providers who prescribe GLP-1s, Yuval Pinto, MD, has worked with select patients to gradually reduce how often they take the medication
Reported Effects Weight reduction (no diabetes): In REDEFINE 1, CagriSema 2.4 mg + 2.4 mg produced roughly 22.7% mean weight loss at 68 weeks (trial-product estimand), though this fell short of the ~25% Novo Nordisk had guided toward [1]
Cloudiness whether it appears immediately or develops over hours to days in storage is a high-confidence indicator that something has gone wrong
Adding strength exercises (bodyweight squats, light weights, resistance bands) a couple of times a week